BCAL Diagnostics (ASX:BDX) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


What is BCAL Diagnostics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BCAL Diagnostics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

ASX:BDX vs TMO, DHR, IDXX: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, BCAL Diagnostics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Margin of Safety % (DCF Earnings Based) falls into.


BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.